Quadrant Biosciences Receives CPT® PLA Code

Quadrant Biosciences Receives CPT® PLA Code

Our company has successfully received a CPT® Proprietary Laboratory Analyses (PLA) Code from the American Medical Association for our autism saliva test, Clarifi ASD.

This PLA code officially became effective on April 1, 2020.

Attaining this alpha-numeric CPT code marks a step forward in the reimbursement process for families interested in the Clarifi autism saliva test.

“Being issued a unique CPT PLA code represents a major step toward securing Medicaid, Medicare, and private payer reimbursement for the Clarifi ASD test,” said CEO and Founder of Quadrant, Rich Uhlig.

“Issuance of this CPT PLA code furthers our overarching objective to make this test available to all patients and families who need it, regardless of means.”

Currently, Clarifi ASD is available in 49 states throughout the country, excluding New York. While it is not yet covered by insurance, it is being offered at an introductory price of $989. In the meantime, insured patients are encouraged to independently submit a claim for potential reimbursement. Families may also utilize their HSA or FSA accounts to cover the expense.

Clarifi ASD must be ordered and administered by a health care provider. After ordering test kits online, they will be shipped directly to the ordering HCP at no cost to the ordering practice.

To read more about this exciting development, please click here.

About The Author

Comments (1)

  • Lorri Gardner

    We are anxiously waiting for the approval process to be completed. I have followed this development for some time. I realize it is not a diagnosis but a tool to facilitate the ultimate decision. In young children this could be very helpful. Keep me posted.

Leave Comment